How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Healthcare and Pharmaceuticals · Forecast 2027–2033
Diabetes Personal Softwares Market
- By Software Type: Blood Glucose Monitoring Apps, Insulin Dose Calculators, Diet and Nutrition Management Software, Physical Activity Tracking Apps, Diabetes Education and Awareness Apps
- By Platform: Mobile Applications (iOS and Android), Web-based Applications, Desktop Software
- By User Type: Patient-focused Software, Healthcare Provider Software, Caregiver Support Applications
- By Integration Capability: Standalone Applications, Integrated with Continuous Glucose Monitors (CGM), Integrated with Insulin Pumps, Electronic Health Record (EHR) Integrated Software
- By Features: Real-time Glucose Monitoring, Medication Management and Reminders, Data Analytics and Reporting, Telemedicine and Remote Monitoring, Community and Social Support Features
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Blood Glucose Monitoring Apps leads By Software Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 16 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 296 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.178 →
- 12 Company Profiles 16 players: SWOT & benchmarking p.186 →
Full report · locked preview
Everything inside the Diabetes Personal Softwares Market report
A complete, evidence-based study - 12 chapters and 124 sections covering market size, segmentation across 5 axes, regional analysis and 16 company profiles, forecast to 2033.
Segmentation covered
Companies profiled
★★★★★ Excellent
16 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Dexcom Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Medtronic plc
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Roche Diabetes Care
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Insulet Corporation
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Tandem Diabetes Care Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Ascensia Diabetes Care
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Bigfoot Biomedical Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →Glooko Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →One Drop Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Livongo Health
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Inc. (now part of Teladoc Health)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →mySugr GmbH (a Roche company)
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →Omada Health Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Welldoc Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Virta Health
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Blood Glucose Monitoring Apps31.7
- Insulin Dose Calculators16.7
- Diet and Nutrition Management Software23.9
- Physical Activity Tracking Apps9.6
- Diabetes Education and Awareness Apps18.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Dexcom Inc.11.3
- Abbott Laboratories21.0
- Medtronic plc12.3
- Roche Diabetes Care7.5
- Insulet Corporation13.1
- Tandem Diabetes Care Inc.6.7
- Others28.1
Segment contribution to growth (%)
Fig. 18 · p.39 →Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America32.5
- Europe22.7
- Asia Pacific21.9
- Latin America12.6
- Middle East and Africa10.3
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Dexcom Inc. | 74 | 86 | 89 | 74 | 98 | 80 | 84 |
| Abbott Laboratories | 68 | 71 | 81 | 88 | 91 | 91 | 82 |
| Medtronic plc | 85 | 87 | 72 | 80 | 64 | 84 | 79 |
| Roche Diabetes Care | 81 | 79 | 64 | 72 | 57 | 77 | 72 |
| Insulet Corporation | 73 | 75 | 52 | 62 | 65 | 77 | 67 |
| Tandem Diabetes Care Inc. | 60 | 71 | 47 | 58 | 62 | 47 | 58 |
| Ascensia Diabetes Care | 56 | 60 | 40 | 48 | 54 | 63 | 54 |
| Bigfoot Biomedical Inc. | 49 | 50 | 40 | 59 | 45 | 44 | 48 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Dexcom Inc.
- Abbott Laboratories
- Medtronic plc
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Dexcom Inc. | ✓ | ◐ | ✓ | ◐ | ◐ | ✓ |
| Abbott Laboratories | ✓ | ✓ | ✓ | ✓ | ✓ | ✓ |
| Medtronic plc | ✓ | ◐ | ◐ | ✓ | − | ✓ |
| Roche Diabetes Care | ◐ | ✓ | ◐ | ✓ | − | ◐ |
| Insulet Corporation | − | ◐ | ◐ | − | ◐ | ◐ |
| Tandem Diabetes Care Inc. | − | ◐ | − | ◐ | ✓ | − |
| Ascensia Diabetes Care | ◐ | − | ◐ | − | ◐ | − |
| Bigfoot Biomedical Inc. | − | ◐ | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →Competitive tiers
§8.4 · p.172 →Leader3
Set the pace on share, breadth and innovation.
Challenger2
Strong scale, closing on the leaders.
Contender1
Focused players with pockets of strength.
Niche2
Specialists in a single segment or region.
Go-to-market strategy
Land Software Type in North America, then scale across Diabetes Personal Softwares Market — a $729M beachhead inside a $10.1B market.
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Blood Glucose Monitoring Apps
Best fit — highest urgency & budget in Software Type.
Insulin Dose Calculators
Strong fit — clear ROI and a fast path to value.
Diet and Nutrition Management Software
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Software Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Platform & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + User Type
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Positioning & messaging
§GTM 2 · p.194 →For Software Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Diabetes Personal Softwares Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Investment thesis
Diabetes Personal Softwares Market is a durable-growth opportunity — $8.11B by 2033, compounding at 6.0%.
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.0% CAGR
Demand compounds through 2033, outpacing GDP across Software Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Software Type moving from early to mainstream — durable secular demand.
Consolidation upside
16+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →Return scenarios (2033 market value)
Fig. 6 · p.22 →Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Platform optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Diabetes Personal Softwares Market — a $7.54B market by 2033. Plan: grow share from 8.8% to 14.3%.
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 8.8% | 14.3% | Ahead |
| Revenue | $675M | $1.08B | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Behind |
| Gross margin | 34.9% | 45.6% | On track |
| Customer retention | 86.7% | 94.0% | On track |
Where to play (strategic priorities)
§1.2 · p.8 →Lead segment
Win in Software Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
Adjacency
Build Platform capability
A defensible second engine — invest in Platform to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Software Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Platform
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $136M capacity & capability investment
- Greenlight bolt-on M&A in Platform
- Authorise North America expansion plan
- Fund R&D program for Software Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskOn track
- Regulatory / policy changeOn track
- Execution & talentBehind
Sales deck · value proposition
Win the Diabetes Personal Softwares Market conversation — a $9.28B market you can size, segment and defend in minutes.
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Software Type
Goal Grow share in Software Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →The business case (ROI)
Fig. 2 · p.9 →Why buyers trust it (proof points)
§1.3 · p.12 →Coverage includes
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Diabetes Personal Softwares Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
Your report is ready to access
Diabetes Personal Softwares Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Healthcare and Pharmaceuticals · scroll →Diabetes Monitoring Devices Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportDiabetes Mellitus Drugs Market
Market size, share, segmentation and regional forecast.
$1.1B market · 2025 base year
View reportDoxazosin Mesylate Market
Market size, share, segmentation and regional forecast.
$4.6B market · 2025 base year
View reportDiabetes Medicines Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportDiabetes Management Software Market
Market size, share, segmentation and regional forecast.
$526M market · 2025 base year
View reportDiabetes Management Products Market
Market size, share, segmentation and regional forecast.
$4.5B market · 2025 base year
View reportDiabetes Management Medical Devices Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportDiabetes Management Insulin Pump and Continuous Glucose Monitors (CGM) Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportDiabetes Management Application Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportDiabetes Lancing Devices Market
Market size, share, segmentation and regional forecast.
$5.6B market · 2025 base year
View reportDiabetes Lancets for Home Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportDiabetes Laboratory Immunoassays Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy